Analysis of Liposomal irinotecan's pharmacokinetics and side effects

Phase 3

Recruiting

• Conditions: Pancreatic cancer; Pancreatic cancer Onyvyde Irinotecan UGT1A1; C535836

• Registration Number: JPRN-jRCT1041200085
• Lead Sponsor: ANDO Yuichi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Pancreatic cancer, underwent UGT1A1 polymorphism test

Exclusion Criteria

Already used Onivyde(Liposomal irinotecan)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of drug concentration of Irinotecan and its metabolites by UGT1A1 gene polymorphism

Secondary Outcome Measures

Name	Time	Method
Secondary Outcome(s)Adverse events, Time to treatment failure, Effectiveness (Response rate, progression-free survival, Overall survival)